Target Price | $112.20 |
Price | $99.02 |
Potential |
13.31%
register free of charge
|
Number of Estimates | 16 |
16 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2026 .
The average Rhythm Pharmaceuticals, Inc. target price is $112.20.
This is
13.31%
register free of charge
$141.75
43.15%
register free of charge
$95.95
3.10%
register free of charge
|
|
A rating was issued by 20 analysts: 19 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2026 of
13.31%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 130.13 | 190.12 |
68.06% | 46.10% | |
EBITDA Margin | -202.83% | -94.16% |
13.99% | 53.58% | |
Net Margin | -203.31% | -103.23% |
14.76% | 49.23% |
16 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2025 . The average Rhythm Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2025. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rhythm Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.34 | -3.07 |
35.63% | 29.26% | |
P/E | negative | |
EV/Sales | 33.64 |
16 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Rhythm Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 29 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 25 2025 |
Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 29 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 25 2025 |
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 24 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 07 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Aug 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.